| Autor: |
Moya-Alarcón C; Health Economics & Outcomes Research, AstraZeneca, Spain., Piera G; Medical Affairs, AstraZeneca, Spain., Callejo Á; Evidence Generation Manager, AstraZeneca, Spain., Gascó A; Global Clinical Program Lead, AstraZeneca, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of comparative effectiveness research [J Comp Eff Res] 2022 Jan; Vol. 11 (1), pp. 13-27. Date of Electronic Publication: 2021 Oct 26. |
| DOI: |
10.2217/cer-2021-0135 |
| Abstrakt: |
Aim: To describe the overall cancer-related healthcare utilization patterns, treatment patterns and outcomes in women diagnosed with platinum-sensitive recurrent high-grade serous ovarian cancer. Patients & methods: Subanalysis of the Spanish sample of a retrospective, noninterventional, multinational, observational study. Results: BRCA -mutated patients had better outcomes in terms of progression-free survival and overall survival than patients who were BRCA wild-type. It was observed that patients' treatment outcomes after the first recurrence progressively worsened as the patient underwent subsequent chemotherapy lines. Healthcare resource utilization when accounting for the follow-up time did not substantially differ between BRCA1 / 2 -mutated and BRCA wild-type patients. Conclusion: BRCA1/2 mutation carriers have better treatment outcomes, including longer survival, without a negative impact on the use of healthcare resources. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
